Search
Drotebanol
go.drugbank.com/drugs/DB01547ExperimentalIllicitCategories: Heterocyclic Compounds with 4 or More RingsAfelimomab
go.drugbank.com/drugs/DB04956ExperimentalAfelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
Ethyl macadamiate
go.drugbank.com/drugs/DB11243ApprovedIt is a non-volatile ester of ethyl alcohol and the fatty acids. … Ethyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products and skin care products as an emollient and skin conditioning agent.
REP8839
go.drugbank.com/drugs/DB05224ExperimentalREP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Dimemorfan
go.drugbank.com/drugs/DB13810ExperimentalCategories: Heterocyclic Compounds with 4 or More RingsLanolin alcohols
go.drugbank.com/drugs/DB14181ApprovedLanolin alcohols are a complex combination of organic alcohols obtained by the hydrolysis of lanolin. … It is administered as an ointment base with topical insulin and has shown to be antagonistic to wound healing. It is commonly used in allergenic testing.
EVT 302
go.drugbank.com/drugs/DB06057InvestigationalEVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.
Flavin adenine dinucleotide
go.drugbank.com/drugs/DB03147ApprovedA condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. … (Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.
AM103
go.drugbank.com/drugs/DB05225ExperimentalAM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation
Laquinimod
go.drugbank.com/drugs/DB06685InvestigationalIt has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally. … It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.